Drug Pricing


  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip

    Medicare to cover Novo’s obesity drug for some patients

    Two weeks after the FDA updated Wegovy’s label, Medicare changed its stance to allow people with a history of heart disease to receive treatment, a shift that could boost access to the fast-selling medicine.

    By March 22, 2024
  • Colorful DNA double helix.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Orchard sets out to sell world’s priciest gene therapy

    Orchard is counting on the long-term data it’s accrued to convince insurers to cover Lenmeldy’s $4.25 million list price, the highest of any genetic medicine to come to market.

    By Kristin Jensen • March 20, 2024
  • Explore the Trendline
    Image attribution tooltip
    Elizabeth Regan / Biopharma Blog
    Image attribution tooltip
    Trendline

    Drug pricing

    Drug pricing legislation has put pharmaceutical companies on the defensive and created a new precedent for the industry.

    By BioPharma Blog staff
  • Kroger Ocado
    Image attribution tooltip
    Courtesy of Kroger
    Image attribution tooltip

    Elevance to buy Kroger’s specialty pharmacy

    Major pharmacy benefit managers continue to double down on specialty as a reliable source of business amid a growing crop of pharmacy upstarts.

    By Rebecca Pifer • March 19, 2024
  • A photo of a Madrigal Pharmaceuticals' MASH drug Rezdiffra.
    Image attribution tooltip
    Courtesy of Madrigal Pharmaceuticals
    Image attribution tooltip

    Madrigal, FDA approval in hand, outlines plan to sell MASH drug

    The company expects initial uptake of Rezdiffra, which costs $47,400 per year, to be slow as doctors and insurers establish the protocols needed to find patients eligible for treatment.

    By March 15, 2024
  • Cigna's logo is seen on a door.
    Image attribution tooltip
    Julia Rendleman via Getty Images
    Image attribution tooltip

    Why Cigna is capping cost increases for pricey obesity drugs

    The first-of-its-kind move comes as pharmacy benefit managers continue to try to prove their value to clients, and shows how major players are working to meet demand for the fast-selling medicines.

    By Rebecca Pifer • March 8, 2024
  • U.S. President Joe Biden gestures with his hands while speaking from behind a podium.
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    Biden proposes strengthening Medicare’s drug pricing power

    The administration seeks to significantly increase the number of drugs each year that would be subjected to price negotiations under provisions of the Inflation Reduction Act.

    By Kristin Jensen • March 7, 2024
  • Judge gavel and pills against blue backdrop
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    AstraZeneca’s drug pricing lawsuit dismissed by federal judge

    The rejection is the latest setback in the pharmaceutical industry’s efforts to use the courts to challenge Medicare’s new pricing powers.

    By March 4, 2024
  • Three people in suits sit on a dias at a Congressional hearing.
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip

    Pharma CEOs, pressed by Senate panel, refuse to commit to price cuts

    Forced into testifying by Senate HELP chair Bernie Sanders, the heads of Bristol Myers Squibb, J&J and Merck largely avoided major missteps.

    By Feb. 8, 2024
  • An illustration of sickled red blood cells blocking a blood vessel.
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    New CMS pilot to test payment scheme for pricey sickle cell gene therapies

    The agency is planning a pilot program across states to help sickle cell patients access treatments like the newly approved Casgevy and Lyfgenia.

    By Jan. 31, 2024
  • U.S. capitol building with stormy skies
    Image attribution tooltip
    Douglas Rissing via Getty Images
    Image attribution tooltip

    Sanders threatens to subpoena J&J, Merck CEOs over drug prices

    The Senate HELP committee, which is seeking testimony from J&J's Joaquin Duato and Merck's Robert Davis, hasn't issued a subpoena since 1981.

    By Jan. 19, 2024
  • A photograph of the exterior of the Food and Drug Administration headquarters in Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA authorizes Florida to import drugs from Canada

    The clearance is a major shift for the agency, which described its decision as a “first step” in allowing Florida to bulk purchase lower-cost Canadian medicines.

    By , Jan. 5, 2024
  • drug pricing protest
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    Humira leads ICER’s latest list of ‘unsupported’ price hikes

    AbbVie’s blockbuster medicine topped a list of treatments that, combined, elevated U.S. healthcare spending by $1.3 billion in 2022, according to the price watchdog’s latest yearly report.

    By Dec. 11, 2023
  • An illustration of sickled red blood cells.
    Image attribution tooltip
    EzumeImages via Getty Images
    Image attribution tooltip

    Pricey new gene therapies for sickle cell pose access test

    Casgevy, the first CRISPR therapy approved by the FDA, will cost $2.2 million, while Bluebird’s competing genetic medicine is priced at $3.1 million.

    By Dec. 8, 2023
  • U.S. President Joe Biden gestures with his hands while speaking from behind a podium.
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    Biden administration goes after drug patents in bid to lower prices

    The White House is supporting a policy that would allow the U.S. government to sidestep patent protections for drugs developed with federal funding and that have prices deemed “extreme, unjustified, and exploitative.”

    By Dec. 7, 2023
  • A window with the logo for Amicus Therapeutics.
    Image attribution tooltip
    Amicus Therapeutics
    Image attribution tooltip

    BIO names longtime Amicus head John Crowley as new CEO

    Crowley, a rare disease advocate who led Amicus for nearly two decades, will take the reins as the industry group seeks to challenge Medicare’s new drug pricing powers.

    By Dec. 5, 2023
  • Workers gather inside BioMarin’s gene therapy manufacturing plant in Novato, California.
    Image attribution tooltip
    Courtesy of BioMarin Pharmaceutical
    Image attribution tooltip

    BioMarin secures hemophilia gene therapy coverage in Germany

    Drawn-out negotiations led to a lower price than initially expected, but analysts called the agreement a step forward for the biotech company.

    By Kristin Jensen • Nov. 29, 2023
  • The Federal Trade Commission headquarters is pictured in Washington, D.C. The agency's proposed noncompete ban may face legal challenges on several grounds.
    Image attribution tooltip
    RiverNorthPhotography via Getty Images
    Image attribution tooltip

    FTC challenges patents held by nine big drugmakers, citing unfair competition

    The agency claims intellectual property for emergency allergy shot EpiPen and asthma medication Advair was “improperly listed” in an FDA database.

    By Nov. 8, 2023
  • A conceptual illustration of neural activity in a brain.
    Image attribution tooltip
    nopparit via Getty Images
    Image attribution tooltip

    Biogen, Sage set price of postpartum depression pill at $15,900

    The price is below what some analysts had predicted and significantly less than $34,000 Sage initially set for its earlier postpartum infusion, Zulresso.

    By Nov. 7, 2023
  • Congressman Garcia gestures to a cardboard meme of two identical Spiderman characters pointing at one another.
    Image attribution tooltip
    Rebecca Pifer/BioPharma Blog
    Image attribution tooltip

    PBMs, PhRMA trade blame over drug costs in House hearing

    Pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA pointed fingers over problems in the prescription supply chain during the House committee's second hearing on the PBM industry.

    By Rebecca Pifer • Sept. 19, 2023
  • Astellas' U.S. headquarters in Northbrook, IL.
    Image attribution tooltip
    Permission granted by Astellas
    Image attribution tooltip

    Astellas withdraws lawsuit challenging Medicare drug price program

    The drugmaker said it still believes the U.S. government’s price negotiation powers are unconstitutional, but is pulling back a lawsuit it filed in July.

    By Sept. 7, 2023
  • Joe Biden stands at a podium flanked on either sides by screens that read: "lowering costs for American families."
    Image attribution tooltip
    Win McNamee / Staff via Getty Images
    Image attribution tooltip

    Medicare named the first 10 drugs up for negotiation. Now what?

    The list of blockbuster cardiovascular, diabetes and cancer drugs gives the industry a window into how regulators are approaching price negotiations.

    By Karissa Waddick • Aug. 30, 2023
  • U.S. President Joe Biden gestures with his hands while speaking from behind a podium.
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    Medicare names first 10 drugs for price negotiations

    The Inflation Reduction Act gave the U.S. government new pricing powers, which CMS put into practice this August with its first slate of blockbuster targets.

    By Updated Aug. 29, 2023
  • Corporate logos are seen outside  on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca the latest pharma to challenge drug pricing law

    The drugmaker's lawsuit follows similar legal challenges from Merck & Co., Bristol Myers Squibb and Johnson & Johnson, among others.

    By Aug. 25, 2023
  • A view from below of the CVS sign on the center of a building, with a vertical blue HealthHub sign to its right.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    CVS launches new venture in biosimilar drug experiment

    The subsidiary, called Cordavis, will work directly with manufacturers to market or co-produce low-cost biologic drugs, starting with Novartis’ Humira copy.

    By Aug. 24, 2023
  • Boehringer sues to block US drug price program

    The pharma’s suit, which claims Medicare’s new power to negotiate certain drug prices is unconstitutional, comes days before the agency will reveal the first 10 medicines to be included under the plan.

    By Aug. 22, 2023